The abstract is read at the publisher; the summary is JClub's.
SMPD1 is validated as a causal plasma protein for abdominal aortic aneurysm, and its inhibition attenuates disease progression in mouse models via ceramide (d18:1/16:0)–mediated NLRP3 inflammation.
- Why it matters: AAA is highly heritable yet lacks effective pharmacotherapy, and the field needs therapeutic targets supported by causal human genetics and mechanistic validation.
- What they did: The study integrated AAA genome-wide association and plasma proteomics using Mendelian randomization, validating 6 causal proteins including SMPD1; they then used SMPD1/ASM-IN-1 and amitriptyline in PPE- and angiotensin II–induced mice, alongside ceramide measurements and rescue experiments, plus single-cell and cell isolation to identify adventitial fibroblasts.
- The result: SMPD1 upregulation in AAA mice is linked to ceramide (d18:1/16:0) and drives an NLRP3 inflammatory pathway, suppressing endothelial/smooth muscle proliferation and promoting apoptosis/autophagy and phenotypic switching; SMPD1 inhibition with amitriptyline attenuated AAA progression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.